The Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS)

Trial Profile

The Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS)

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Apr 2017

At a glance

  • Drugs Somatropin (Primary)
  • Indications Growth disorders; Short stature; Somatotropin deficiency; Turner's syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GeNeSIS
  • Sponsors Eli Lilly
  • Most Recent Events

    • 19 Apr 2017 New trial record
    • 04 Apr 2017 Results (n=5076) analysing near adult height gains in Somatropin treated children with growth disorders from the GeNeSIS observational study, presented at The 99th Annual Meeting of the Endocrine Society.
    • 04 Apr 2017 Results (n=21,178) evaluating the safety in Somatropin treated pediatric patients of all short stature diagnoses who participated in the GeNeSIS observational study, presented at The 99th Annual Meeting of the Endocrine Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top